{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:09Z","timestamp":1792601469728,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We aim to evaluate the efficacy of brentuximab vedotin (BV) combined with gemcitabine (GBV) followed by BV maintenance in relapsed or refractory (R\/R) peripheral T-cell lymphoma (PTCL). Patients with at least 5% CD30+ cells by immunohistochemistry received 4 GBV induction (28 days) cycles of gemcitabine 1000 mg\/m2 (day 1, day 15) plus BV 1.8 mg\/kg (day 8) followed, in responding patients, by up to 12 BV maintenance (21 day) cycles. Primary end point was overall response rate (ORR) after 4 induction cycles by computed tomography scan\u2013based Lugano criteria. Of 71 enrolled patients (median age of 66 years), 80.3% had received 1 previous line and 60.6% were refractory. The diagnoses per pathology central review were follicular helper T-cell lymphomas (TFHL; 47.9%), anaplastic large-cell lymphomas (ALCL; anaplastic lymphoma kinase [ALK] negative [19.7%] and ALK+ [7%]), peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS; 12.7%), and other entities (12.7%). In the intention-to-treat analysis, ORR was 46.5%, with 19.7% complete response. Twenty-eight patients received maintenance. Grade 3 to 4 adverse events reported in \u226510% of patients during induction comprised neutropenia (55%), thrombocytopenia (14%), anemia (21%), and infection (14%); during maintenance comprised neutropenia (39%), thrombocytopenia (21%), and peripheral neuropathy (14%). With a median follow-up of 32.6 months, the median duration of response, progression-free, and overall survival were 15.8, 4.5, and 12.9 months, respectively. Efficacy, higher in ALCL, was present in the TFHL and PTCL-NOS group. A negative association of high baseline soluble CD30 on both response and survival was found, which, in ad hoc analysis, appeared highly relevant in patients with TFHL and PTCL-NOS. This trial was registered at the European Union Drug Regulating Authorities Clinical Trials database as #2017-000409-1, and at www.clinicaltrials.gov as #NCT03496779.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015787","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:57:52Z","timestamp":1754337472000},"page":"6292-6304","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-621X","authenticated-orcid":false,"given":"Olivier","family":"Tournilhac","sequence":"first","affiliation":[{"name":"1Department of Hematology and Cell Therapy, Clermont-Ferrand University Hospital, Universit\u00e9 Clermont, Auvergne, EA7453 Chelter Centre d'Investigation Clinique-1405, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-149X","authenticated-orcid":false,"given":"Sol\u00e8ne","family":"Lecolant","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hacini","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Centre Hospitalier Chambery, Chambery, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bailly","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Cell Therapy, Clermont-Ferrand University Hospital, Universit\u00e9 Clermont, Auvergne, EA7453 Chelter Centre d'Investigation Clinique-1405, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1220-726X","authenticated-orcid":false,"given":"Thibaut","family":"Belmondo","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"},{"name":"6Department of Hematology, Cr\u00e9teil University Hospital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Maerevoet","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-7261","authenticated-orcid":false,"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-5591","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier Universitaire Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-2128","authenticated-orcid":false,"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Institut Curie, Saint Cloud, Universit\u00e9 de Versailles Saint-Quentin, Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bonnet","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Service d\u2019h\u00e9matologie, Centre Hospitalier Universitaire de Li\u00e8ge, Li\u00e8ge Universit\u00e9, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-810X","authenticated-orcid":false,"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Centre Hospitalier Universitaire Universit\u00e9 Catholique de Louvain, Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Dupuis","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Centre Hospitalier Universitaire Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Centre Hospitalier Universitaire Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Daguindau","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Centre Hospitalier Annecy, Annecy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Centre Hospitalier Universitaire Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tricot","sequence":"additional","affiliation":[{"name":"18Centre Hospitalier Valenciennes, Valenciennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-0655","authenticated-orcid":false,"given":"Charline","family":"Moulin","sequence":"additional","affiliation":[{"name":"19Department of Hematology, University Hospital of Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Banos","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Centre Hospitalier Universitaire Bayonne, Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-8213","authenticated-orcid":false,"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Centre Hospitalier Universitaire Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Chauchet","sequence":"additional","affiliation":[{"name":"22Department of Hematology, Centre Hospitalier Universitaire Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Centre Hospitalier Universitaire Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Farhat","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Centre Hospitalier Universitaire Versailles, Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-007X","authenticated-orcid":false,"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Drenou","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Centre Hospitalier Universitaire Mulhouse, Mulhouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacene","family":"Zerazhi","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Centre Hospitalier Avignon, Avignon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-625X","authenticated-orcid":false,"given":"David","family":"Sibon","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"},{"name":"29Department of Hematology, Centre Hospitalier Universitaire Necker, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[{"name":"30Department of Hematology, Centre R\u00e9gional de Lutte Contre le Cancer Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Delette","sequence":"additional","affiliation":[{"name":"31Department of Hematology, Centre Hospitalier Universitaire Amiens, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Snauwaert","sequence":"additional","affiliation":[{"name":"32Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bailly","sequence":"additional","affiliation":[{"name":"33Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Centre Hospitalier Universitaire Necker, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-7914","authenticated-orcid":false,"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"34Department of Hematology, Centre Hospitalier Universitaire Grenoble, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Ledoux-Pilon","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Cell Therapy, Clermont-Ferrand University Hospital, Universit\u00e9 Clermont, Auvergne, EA7453 Chelter Centre d'Investigation Clinique-1405, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-4138","authenticated-orcid":false,"given":"Marie-C\u00e9cile","family":"Parrens","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Griolet","sequence":"additional","affiliation":[{"name":"35Department of Statistics, Lymphoma Study Association Recherche Clinique Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-905X","authenticated-orcid":false,"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[{"name":"36Department of Pathology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[{"name":"3Department of Immunology, Centre Hospitalier Universitaire Cr\u00e9teil, University Hospital Henri Mondor, University Paris-Est Cr\u00e9teil and INSERM U955, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-516X","authenticated-orcid":false,"given":"Laurence","family":"de Leval","sequence":"additional","affiliation":[{"name":"37Department of Laboratory Medicine and Pathology, University Hospital and Lausanne University, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi Laurent","family":"Damaj","sequence":"additional","affiliation":[{"name":"38Department of Hematology, Haematology Institute and University of Caen, CRNS, ISTCT UMR6030, GIP Cyceron, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"18","key":"2025122309361250000_bib1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"JCO"},{"issue":"16","key":"2025122309361250000_bib2","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"JCO"},{"issue":"5","key":"2025122309361250000_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"2025122309361250000_bib4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"36","key":"2025122309361250000_bib5","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"JCO"},{"issue":"9","key":"2025122309361250000_bib6","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3390\/cancers14092332","article-title":"Peripheral T-cell lymphomas: therapeutic approaches","volume":"14","author":"Sibon","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"2025122309361250000_bib7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"2025122309361250000_bib8","first-page":"JCO2400554","article-title":"Long-term follow-up of the prospective randomized AATT study (autologous or allogeneic transplantation in patients with peripheral T-cell lymphoma)","author":"Tournilhac","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025122309361250000_bib9","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2022007425","article-title":"Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis","volume":"6","author":"Shafagati","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2025122309361250000_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol"},{"issue":"18","key":"2025122309361250000_bib11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"JCO"},{"issue":"25","key":"2025122309361250000_bib12","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2025122309361250000_bib13","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2025122309361250000_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.2963","article-title":"Brentuximab vedotin in the treatment of relapsed\/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study","volume":"40","author":"Stefoni","year":"2022","journal-title":"Hematol Oncol"},{"issue":"2","key":"2025122309361250000_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of brentuximab vedotin in relapsed or refractory high-CD30\u2013expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"10","key":"2025122309361250000_bib16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"issue":"8","key":"2025122309361250000_bib17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025122309361250000_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025122309361250000_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2025122309361250000_bib20","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2025122309361250000_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V126.23.341.341","article-title":"First multicenter, randomized phase 3 study in patients (Pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator\u2019s choice (Lumiere trial; NCT01482962)","volume":"126","author":"O\u2019Connor","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2025122309361250000_bib22","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025122309361250000_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2025122309361250000_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.23838\/pfm.2019.00135","article-title":"Determination of cutoff values for biomarkers in clinical studies","volume":"4","author":"Woo","year":"2020","journal-title":"Precis Future Med"},{"issue":"10168","key":"2025122309361250000_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"The Lancet"},{"issue":"3","key":"2025122309361250000_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"19","key":"2025122309361250000_bib27","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1182\/bloodadvances.2022008524","article-title":"Salvage therapy with brentuximab-vedotin and bendamustine for patients with R\/R PTCL: a retrospective study from the LYSA group","volume":"7","author":"Aubrais","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025122309361250000_bib28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3324\/haematol.2017.171355","article-title":"Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed\/refractory systemic anaplastic large cell lymphoma","volume":"102","author":"Broccoli","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2025122309361250000_bib29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5045\/br.2023.2023206","article-title":"A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803\/BRAVO study","volume":"58","author":"Kim","year":"2023","journal-title":"Blood Res"},{"issue":"4","key":"2025122309361250000_bib30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjh.17896","article-title":"Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data","volume":"196","author":"Halligan","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025122309361250000_bib31","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2025122309361250000_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients; evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"14","key":"2025122309361250000_bib33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"JCO"},{"issue":"10","key":"2025122309361250000_bib35","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/bloodadvances.2023011030","article-title":"Nivolumab plus brentuximab vedotin for relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"8","author":"Zinzani","year":"2024","journal-title":"Blood Adv"},{"issue":"32","key":"2025122309361250000_bib36","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"JCO"},{"issue":"10094","key":"2025122309361250000_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"The Lancet"},{"issue":"8","key":"2025122309361250000_bib38","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2021.278301","article-title":"A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"issue":"32","key":"2025122309361250000_bib39","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in Mycosis Fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025122309361250000_bib40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/0008-5472.CAN-06-2470","article-title":"ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro","volume":"67","author":"Eichenauer","year":"2007","journal-title":"Cancer Res"},{"issue":"20","key":"2025122309361250000_bib41","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1242\/dev.076398","article-title":"Ectodomain shedding and ADAMs in development","volume":"139","author":"Weber","year":"2012","journal-title":"Development"},{"issue":"13","key":"2025122309361250000_bib42","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","article-title":"Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin\u2019s lymphoma: a study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Casasnovas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025122309361250000_bib43","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/bloodadvances.2023010441","article-title":"Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma","volume":"8","author":"O\u2019Connor","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2025122309361250000_bib44","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"23","key":"2025122309361250000_bib45","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025122309361250000_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"JCO"},{"issue":"10","key":"2025122309361250000_bib47","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2017.1295143","article-title":"Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials","volume":"58","author":"Shustov","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025122309361250000_bib48","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025122309361250000_bib49","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025122309361250000_bib50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2025122309361250000_bib51","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6292\/2474230\/blooda_adv-2024-015787-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6292\/2474230\/blooda_adv-2024-015787-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:36:25Z","timestamp":1766500585000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6292\/546474\/Brentuximab-vedotin-addition-to-gemcitabine-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":50,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015787","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,10]]}}}